Rocket Pharmaceuticals
RCKTRocket Pharmaceuticals is a late-stage biotechnology company developing genetic therapies for rare and fatal diseases, with a primary focus on inherited cardiomyopathies.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Rocket Pharmaceuticals is a late-stage biotechnology company developing genetic therapies for rare and fatal diseases, with a primary focus on inherited cardiomyopathies. The company utilizes a multi-platform approach involving both adeno-associated virus (AAV) and lentiviral (LV) vectors to address the underlying genetic causes of disease. Their value proposition is built on a fully integrated model that includes in-house cGMP manufacturing and a portfolio of first-in-class or best-in-class product candidates.
A leading late-stage gene therapy developer with proprietary in-house AAV manufacturing and multiple first-in-class designations from the FDA and EMA.
Questions, answered.
- What is Rocket Pharmaceuticals's market cap?
- Rocket Pharmaceuticals (RCKT) has a market capitalization of $354.9M and trades on NASDAQ.
- Who are Rocket Pharmaceuticals's competitors?
- Rocket Pharmaceuticals's key competitors include Beam Therapeutics, Sarepta Therapeutics, Lexeo Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Rocket Pharmaceuticals partner with?
- Rocket Pharmaceuticals's notable partners include REGENXBIO Inc., The Regents of the University of California, Temple University, and others.
- What subsidiaries does Rocket Pharmaceuticals have?
- Rocket Pharmaceuticals's subsidiaries include Renovacor, Rocket Pharmaceuticals, Ltd..
- Where is Rocket Pharmaceuticals headquartered?
- Rocket Pharmaceuticals is headquartered in United States of America and employs approximately 268 people. It has been publicly traded since 2015.